The extent of cytokine release is directly linked to the risk and severity of AKI, as demonstrated by elevated baseline levels of inflammatory markers such as CRP, LDH, ferritin, and procalcitonin in COVID-19-associated AKI patients, with even higher levels in those requiring renal replacement therapy (RRT) [24]. This evidence concerns the gene CRP and COVID-19.